Economics of SchizophreniaMassimo Moscarelli |
Common terms and phrases
agranulocytosis allocation analysis antipsychotic approach areas assertive community treatment benefits billion British Journal broker model programme ceutical characteristics chlorpromazine clinical data clinical team programme clinical trials clozapine cost functions cost variation cost-effectiveness cost-of-illness studies cost-utility analysis costs and outcomes diagnostic disease drug Drummond economic analyses economic burden economic evaluation economists effectiveness efficacy extrapyramidal side-effects factors funds gramme groups guidelines haloperidol health care expenditures health economics health service costs hospital impact in-patient indirect cost intensive broker model interventions investment Journal of Psychiatry Knapp management programmes marginal cost ment mental disorders mental health services Moscarelli multivariate needs NSAIDs out-patient PACT adaptation programme patients pharmaceutical production psychiatric psychiatric hospital purchasers randomised RCTs reduced research policy residential risperidone Rupp Sartorius schizophrenia sciences sector service users severe mental illness social societal staffed subjects substance misuse symptoms therapies three case management tion treatment costs